Chronic Heart Failure - COngestion eValuation
CHF-COV
Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)
2 other identifiers
interventional
200
1 country
2
Brief Summary
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2021
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 11, 2021
CompletedFirst Posted
Study publicly available on registry
October 22, 2021
CompletedStudy Start
First participant enrolled
December 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 14, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 14, 2029
June 5, 2023
March 1, 2023
7 years
October 11, 2021
June 2, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Rate of death from all causes
composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 2)
24 months after day hospitalization or consultation
Rate of hospitalisation for acute heart failure
composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 1)
24 months after day hospitalization or consultation
Secondary Outcomes (17)
Rate of death from all causes
24 months after day hospitalization or consultation
Rate of hospitalisation for acute heart failure
24 months after day hospitalization or consultation
Rate of hospitalisation for cardiovascular reason
24 months after day hospitalization or consultation
Rate of death from all causes
24 months after day hospitalization or consultation
Rate of hospitalisation for acute heart failure
24 months after day hospitalization or consultation
- +12 more secondary outcomes
Study Arms (1)
Patients with chronic heart failure coming for scheduled day hospitalization
EXPERIMENTAL* Clinical examination focusing on congestion * Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds * Blood sample retrieved for biological assessment and biobanking * Telephone follow-up
Interventions
Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Eligibility Criteria
You may qualify if:
- Patients with chronic acute heart failure admitted in hospital for scheduled day hospitalization or consultation
- Age ≥18 years
- Patients having received complete information regarding the study design and having signed their informed consent form.
- Patient affiliated to or beneficiary of a social security scheme.
You may not qualify if:
- Comorbidity for which the life expectancy is ≤ 3 months
- History of lobectomy or pneumonectomy lung surgery
- Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
- Pregnant woman, parturient or nursing mother
- Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
- Adult person who is unable to give consent
- Person deprived of liberty by a judicial or administrative decision,
- Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHRU de Nancy
Vandœuvre-lès-Nancy, 54500, France
CHRU de Nancy
Vandœuvre-lès-Nancy, 54500, France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 11, 2021
First Posted
October 22, 2021
Study Start
December 14, 2021
Primary Completion (Estimated)
December 14, 2028
Study Completion (Estimated)
June 14, 2029
Last Updated
June 5, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share